Adverum Biotechnologies Inc (ADVM)
7.53
+0.12
(+1.62%)
USD |
NASDAQ |
Nov 04, 16:00
7.53
0.00 (0.00%)
After-Hours: 20:00
Adverum Biotechnologies Revenue (Quarterly)
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
Date | Value |
---|---|
March 31, 2023 | 3.60M |
December 31, 2022 | |
September 30, 2022 | |
June 30, 2022 | |
March 31, 2022 | |
December 31, 2021 | |
September 30, 2021 | |
June 30, 2021 | |
March 31, 2021 | 7.50M |
December 31, 2020 | |
September 30, 2020 | |
June 30, 2020 | |
March 31, 2020 | |
December 31, 2019 | |
September 30, 2019 | 0.25M |
June 30, 2019 | |
March 31, 2019 | |
December 31, 2018 | 0.07M |
September 30, 2018 | 0.833M |
Date | Value |
---|---|
June 30, 2018 | 0.493M |
March 31, 2018 | 0.216M |
December 31, 2017 | 0.461M |
September 30, 2017 | 0.463M |
June 30, 2017 | 0.463M |
March 31, 2017 | 0.462M |
December 31, 2016 | 0.488M |
September 30, 2016 | 0.395M |
June 30, 2016 | 0.307M |
March 31, 2016 | 0.265M |
December 31, 2015 | 0.96M |
September 30, 2015 | 0.953M |
June 30, 2015 | 0.203M |
March 31, 2015 | 0.203M |
December 31, 2014 | 0.203M |
September 30, 2014 | 0.204M |
June 30, 2014 | 0.135M |
March 31, 2014 | 0.03M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
3.60M
Minimum
Mar 2023
7.50M
Maximum
Mar 2021
5.55M
Average
5.55M
Median
Revenue (Quarterly) Benchmarks
EyePoint Pharmaceuticals Inc | 9.477M |
Cassava Sciences Inc | -- |
Regenxbio Inc | 22.30M |
Editas Medicine Inc | 0.513M |
Apellis Pharmaceuticals Inc | 199.68M |
Revenue (Quarterly) Related Metrics
Net Income (Quarterly) | -18.48M |
Total Expenses (Quarterly) | 20.88M |
EPS Diluted (Quarterly) | -0.89 |
Enterprise Value | -19.69M |
Earnings Yield | -106.1% |
Normalized Earnings Yield | -193.89 |